Precious Metals

[gfp927z]

Blade, $700 mil, nice. Thanks for the heads up. It does look like fairly low risk, being a 505-b type approval and considering the company's large cash hoard. When I first saw it was apomorphine and a sublingual route of administration, I figured there could be concerns from the FDA over the abuse potential, but it turns out that apomorphine is not an opioid and doesn't bind to opioid receptors at all. The current market cap looks cheap.

I've been following several small cap bios, AVXL and CTIX, though no current positions. Btw, did you hold your CEMP thru the TTPH blowup? Looks like CEMP is recovering nicely, but TTPH really got plastered, though might have some short term potential as a bottom play. Ah, just another day in the bio sandbox :o)